Natixis Advisors L.P. boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.0% in the first quarter, Holdings Channel.com reports. The fund owned 163,783 shares of the medical equipment provider’s stock after buying an additional 18,815 shares during the quarter. Natixis Advisors L.P.’s holdings in Zimmer Biomet were worth $26,218,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of ZBH. BlackRock Inc. increased its holdings in Zimmer Biomet by 23.9% in the fourth quarter. BlackRock Inc. now owns 19,395,694 shares of the medical equipment provider’s stock valued at $2,988,683,000 after purchasing an additional 3,738,953 shares during the last quarter. Viking Global Investors LP increased its stake in shares of Zimmer Biomet by 128.8% in the 4th quarter. Viking Global Investors LP now owns 3,867,074 shares of the medical equipment provider’s stock valued at $595,877,000 after acquiring an additional 2,176,989 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Zimmer Biomet by 2.1% in the 4th quarter. Bank of New York Mellon Corp now owns 2,023,426 shares of the medical equipment provider’s stock valued at $311,792,000 after acquiring an additional 41,605 shares during the period. Norges Bank bought a new position in Zimmer Biomet during the 4th quarter worth approximately $304,733,000. Finally, Ceredex Value Advisors LLC boosted its stake in Zimmer Biomet by 38.7% during the 4th quarter. Ceredex Value Advisors LLC now owns 1,455,992 shares of the medical equipment provider’s stock worth $224,701,000 after acquiring an additional 406,268 shares during the last quarter. 87.17% of the stock is currently owned by institutional investors.
ZBH opened at $167.27 on Monday. The business’s 50-day simple moving average is $169.51 and its 200 day simple moving average is $157.49. Zimmer Biomet Holdings, Inc. has a 52-week low of $110.53 and a 52-week high of $180.36. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 2.18. The firm has a market capitalization of $34.87 billion, a PE ratio of 1,045.50, a PEG ratio of 4.32 and a beta of 1.34.
The company also recently declared a quarterly dividend, which was paid on Friday, April 30th. Shareholders of record on Monday, March 29th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.57%. The ex-dividend date was Friday, March 26th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 12.20%.
In other news, Director Arthur J. Higgins acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, May 6th. The stock was bought at an average price of $171.58 per share, with a total value of $171,580.00. Following the transaction, the director now directly owns 3,400 shares in the company, valued at approximately $583,372. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.44% of the company’s stock.
Several equities analysts have recently issued reports on the stock. JMP Securities boosted their price target on shares of Zimmer Biomet from $180.00 to $195.00 and gave the company an “outperform” rating in a report on Tuesday, May 11th. Oppenheimer lifted their target price on Zimmer Biomet from $185.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, May 5th. Raymond James raised their price target on Zimmer Biomet from $187.00 to $200.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, May 11th. BTIG Research boosted their price objective on Zimmer Biomet from $160.00 to $173.00 and gave the company a “buy” rating in a research report on Monday, January 25th. Finally, Northland Securities upgraded shares of Zimmer Biomet from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $165.00 to $200.00 in a report on Thursday, April 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $177.95.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T.
Featured Article: How to read a candlestick chart
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.